{"id":"aripiprazole-bms-337039","safety":{"commonSideEffects":[{"rate":"10-25%","effect":"Akathisia"},{"rate":"15-27%","effect":"Headache"},{"rate":"10-20%","effect":"Anxiety"},{"rate":"10-25%","effect":"Insomnia"},{"rate":"8-15%","effect":"Nausea"},{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5-15%","effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL2219425","moleculeType":"Small molecule","molecularWeight":"660.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole acts as a partial agonist rather than a full antagonist, meaning it can both activate and inhibit dopamine D2 receptors depending on baseline dopamine levels, providing a stabilizing effect on dopaminergic signaling. This unique mechanism, combined with 5-HT1A partial agonism, reduces both positive and negative symptoms of psychosis while potentially causing fewer extrapyramidal side effects than typical antipsychotics. The partial agonist activity allows for dopaminergic tone adjustment rather than complete blockade.","oneSentence":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:16.330Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic and mixed episodes)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Irritability associated with autism spectrum disorder"}]},"trialDetails":[{"nctId":"NCT00261443","phase":"PHASE4","title":"A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-09","conditions":"Bipolar Disorder","enrollment":1270},{"nctId":"NCT00239356","phase":"PHASE3","title":"Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2003-03","conditions":"Schizophrenia","enrollment":119},{"nctId":"NCT01227668","phase":"PHASE4","title":"Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":"Irritability Associated With Autistic Disorder","enrollment":215},{"nctId":"NCT00508157","phase":"PHASE4","title":"A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Metabolic Syndrome, Schizophrenia","enrollment":125},{"nctId":"NCT01438060","phase":"PHASE3","title":"Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2000-08","conditions":"Dementia, Alzheimer Type","enrollment":232},{"nctId":"NCT00665366","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-06","conditions":"Bipolar Disorder Mania","enrollment":493},{"nctId":"NCT00277212","phase":"PHASE4","title":"A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-12","conditions":"Bipolar Disorder","enrollment":1169},{"nctId":"NCT00365859","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-09","conditions":"Autistic Disorder, Behavioral Symptoms","enrollment":330},{"nctId":"NCT00232687","phase":"PHASE4","title":"A Switch Study of BMS-337039 in Schizophrenic Out-patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-06","conditions":"Schizophrenia","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Aripiprazole (BMS-337039)","genericName":"Aripiprazole (BMS-337039)","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission in the brain. Used for Schizophrenia, Bipolar I disorder (acute manic and mixed episodes), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}